Orthobiologics in 2025 and Beyond.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Orthobiologics are biologic substances intended to enhance healing and treat a range of musculoskeletal pathologies. Commonly well-studied orthobiologics such as platelet-rich plasma, bone marrow aspirate concentrate, and micro-fragmented adipose tissue have more than 2 decades of scientific research and clinical use, although with variable outcomes. It is important to discuss both current utilization and future applications of the aforementioned orthobiologics while elucidating some novel orthobiologics with recent regulatory approval, and finally, those orthobiologics on the horizon and beyond. Orthopaedic applications of mesenchymal stem or stromal cells, cell-based cartilage implants, and perinatal cell-derived therapies all hold promise to treat a broad range of musculoskeletal ailments. The Biologic Association and American Academy of Orthopaedic Surgeons are at the forefront of these emerging technologies, cooperating together on behalf of their membership to provide resources for the purpose of scientific discovery, clinical validation, and translation of novel orthobiologic therapies.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.